Frontotemporal Dementia
Frontotemporal dementia (FTD) is a group of progressive brain diseases that mainly damage the frontal and temporal lobes, the regions that govern personality, behaviour, language, judgement and social awareness. Unlike Alzheimer’s disease, which usually begins with memory loss, FTD more often starts with a change in who someone seems to be, or with speech and language breaking down.
It is one of the leading causes of dementia in people of working age, with symptoms commonly beginning between 45 and 65, although both younger and older onsets occur. In the UK it accounts for about 12% of young onset dementia, where symptoms start before 65, compared with only around 2% of dementia in older people. Across all ages it remains a smaller share of total dementia - typically under 5% because Alzheimer’s and vascular dementia dominate later life. A 2025 global meta analysis in JAMA Neurology estimated a prevalence of about 9 per 100,000 people and an incidence of about 2.3 new cases per 100,000 person years, and the long running PiPPIN study in Cambridgeshire and Norfolk found similar rates.
There is still no cure and no licensed drug that slows FTD, but support, symptom control and early planning can make a substantial difference. Dementia Hub covers what FTD is, how it presents and progresses, medicines, non drug care, coping and research.
What is Frontotemporal Dementia
FTD is caused by the death of nerve cells in the frontal and/ or temporal lobes, where abnormal protein builds up inside those cells. The three main proteins involved are tau, TDP-43 and, less often, FUS, although which protein is responsible cannot usually be known in life without a genetic clue or, after death, a brain examination.
Clinicians group FTD by the symptoms that come first.
Behavioural variant FTD (bvFTD) is the most common form and is marked by changes in personality, social behaviour and emotional control. People may become disinhibited, apathetic, or locked into rigid, compulsive routines that those closest to them do not recognise.
Primary progressive aphasia (PPA) is the form in which language is the main problem at the start, and there are three recognised patterns. In non fluent / agrammatic variant PPA (nfvPPA), speech is effortful and hesitant and grammar breaks down, although understanding is often better than speaking at first. In semantic variant PPA (svPPA), words lose their meaning, so speech can sound fluent but empty, and people may stop recognising familiar objects or faces. In logopenic variant PPA (lvPPA), there are word finding pauses and difficulty repeating sentences; this pattern is often caused by Alzheimer’s pathology rather than frontotemporal lobar degeneration, so many specialists no longer count it as typical FTD.
FTD with motor neurone disease (FTD-MND) describes the minority who develop muscle weakness, twitching, swallowing problems or breathing difficulty similar to amyotrophic lateral sclerosis (ALS). About one or two in ten people with FTD develop a related movement disorder, more often with bvFTD than with semantic PPA.
Closely related conditions on the same spectrum include progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), which share overlapping pathology and sometimes genetics.
A family history is common, but it is not true that up to 40% of all FTD is inherited, because the risk depends on the subtype. In bvFTD, around 40 to 45% of people have a relevant family history; FTD-MND is genetic in roughly 20 to 40%; non-fluent PPA is genetic in about 5 to 10%; and semantic PPA is rarely inherited. Most familial FTD is caused by one of three genes - C9orf72 (the most common worldwide), GRN (progranulin) and MAPT (tau) - each of which accounts for a single-digit percentage of all FTD but a much higher share of clearly familial disease. Many cases remain sporadic, with no mutation found, and genetic counselling should always come before any test.
FTD used to be called Pick’s disease, although that older name is now reserved for a specific tau pathology.
Frontotemporal Symptoms
Symptoms depend on which lobe is affected first, and because memory is often relatively spared early on, GPs may first suspect depression, bipolar disorder, relationship breakdown or a mid life crisis rather than dementia.
In behavioural variant FTD, people may make socially inappropriate remarks, lose their manners, spend impulsively or, sometimes, behave in ways that would once have been unthinkable, including out of character legal trouble. Apathy can look like dropping hobbies, work and hygiene; empathy may blunt so that partners describe living with a stranger; and rigid routines, hoarding, sweet cravings or overeating often appear alongside poor judgement and little insight, so the person frequently does not accept that anything is wrong.
In primary progressive aphasia the picture is linguistic. People with nfvPPA struggle to get words out and produce short, telegraphic sentences that sound effortful. Those with svPPA may know the word “orange” but not what an orange is and, later, have difficulty recognising people. Those with lvPPA have “tip of the tongue” pauses and trouble repeating a sentence.
When FTD overlaps with motor neurone disease or a related motor syndrome, muscle wasting, twitching (fasciculations), falls, stiffness, slowness or a Parkinson’s-like walk may appear, and swallowing problems raise the risk of pneumonia. Other common features include trouble planning, organising and switching tasks, changed food preferences and, later, signs of PSP or corticobasal syndrome such as falls, rigid limbs or eye-movement problems.
Symptoms usually creep in, and families often look back and realise that the first odd year was the disease.
Frontotemporal Dementia Progression
The course is uneven. From first symptoms to death the span is often quoted as wide as 2 to 20 years, while the NHS gives an average of around 8 to 10 years from the start of symptoms, again with some wide variations. Survival from diagnosis is shorter because the diagnosis itself is frequently delayed. In the UK PiPPIN study, median survival from diagnosis was about 4 years for bvFTD, 6 years for PPA and under 3 years for PSP, and FTD-MND often runs to 2 to 5 years once motor neurone disease is established. Younger age at onset, earlier diagnosis and fewer other illnesses are linked with longer survival.
In the early stage the changes are subtle, so work errors, tactless comments or a new fussiness about food get blamed on stress, and people may still live independently. This is the time when lasting powers of attorney and future care wishes should be discussed, while the person can still take part.
In the middle stage, behaviour or language problems disrupt daily life, and finances, driving, childcare and friendships come under strain as the need for supervision grows and motor symptoms may appear.
In the late stage, full time care is usually needed. Speech may fade to mutism in PPA, while in bvFTD disinhibition often gives way to profound apathy. Swallowing failure, immobility and infections - especially pneumonia - are common final events.
Genetic forms do not all move at the same speed: some C9orf72 illnesses progress quickly and others do not. Regular review by a neurologist or cognitive clinic helps families plan the next step rather than wait for a crisis.
Drugs and Treatments
No medicine stops or reverses FTD. NICE and Alzheimer’s Society are clear that cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, which are used in Alzheimer’s disease, are not recommended in FTD and can worsen behaviour.
Treatment is therefore aimed at the most distressing symptoms, at the lowest effective dose, and with regular review.
For behavioural variant FTD, SSRIs such as sertraline, citalopram or escitalopram are the usual first medicines for disinhibition, compulsive eating or irritability, and trazodone is sometimes used for agitation or sleep. The evidence is modest, but these drugs are familiar to UK clinics. Stimulants such as methylphenidate are occasionally tried for apathy, although the evidence is weak. Antipsychotics such as quetiapine or risperidone are a last resort when someone is at serious risk of harm, because they increase stroke and death risk in dementia and can cause stiffness and sedation, so they should be used at the smallest dose for the shortest time.
No drug restores words in PPA, and an Alzheimer medicine should not be started in the hope that it will help speech.
When FTD overlaps with motor neurone disease, riluzole may be offered, although the benefit is modest. Levodopa is sometimes tried if Parkinsonism is prominent, as in corticobasal syndrome, but it often helps little.
Medicines with a heavy anticholinergic load should be avoided where possible because they cloud thinking further, and any new prescription should be agreed with the specialist who knows the diagnosis.
Non - Pharma Treatments
Non drug care is the foundation of living with FTD.
Speech and language therapy is essential in PPA, because therapists can teach residual communication strategies and introduce aids such as communication books, tablet apps and gesture, with the aim of keeping conversation usable for as long as possible rather than restoring perfect speech.
Behavioural support works better than confrontation. A calm, predictable routine, the removal of easy targets for impulsive spending or unsafe cooking, and coaching for caregivers in how to step away from arguments the person can no longer follow all reduce distress more reliably than reasoning.
Occupational therapy simplifies washing, dressing and meals and flags home hazards, while physiotherapy helps walking, transfers and fall prevention when motor symptoms appear.
Psychological support for the family is not optional, because partners often grieve someone who is still in the room. Early stage peer groups, including those run by Rare Dementia Support, which is linked to University College London, and by Alzheimer’s Society, reduce that isolation.
Palliative and hospice care should be introduced before the final crisis, so that comfort, swallowing safety, pain control and honest talk about feeding and hospital admissions are already in place. NICE also recommends considering structured cognitive stimulation and occupational therapy for daily function in mild to moderate dementia of any type.
Coping Mechanisms
FTD hits families in working life, colliding with mortgages, teenagers, jobs and a diagnosis that neighbours may not recognise as dementia.
For the person with FTD, remaining strengths such as music, walking or practical tasks can still give shape to the day, and communication apps help some people with PPA. Wishes for future treatment should be recorded while language and judgement still allow, and counselling can help when insight is preserved, especially in PPA, where people know they are losing words.
Carers need to learn the condition so that rudeness or indifference is seen as brain disease rather than a choice, and to build in rest before burnout arrives. The local authority can provide a carer’s assessment, and respite, day services and Admiral Nurse support through Dementia UK are worth asking about. A specialist FTD group often fits better than a generic dementia group that focuses mainly on memory.
In the UK, lasting powers of attorney should be arranged for health and welfare and for property and financial affairs, and an advance decision can record treatment preferences. Eligibility for Attendance Allowance or Personal Independence Payment, Carer’s Allowance and, later, NHS continuing healthcare should be checked. A diagnosis does not automatically stop driving, but the DVLA and the insurer must be told.
At home, walkways should be kept clear, access to bank cards and the cooker may need to be controlled if impulsivity is severe, and mealtimes may have to be simplified if sweet craving or overeating is a problem.
Useful contacts include the Alzheimer’s Society Dementia Support Line on 0333 150 3456, Rare Dementia Support, Dementia UK and, where there is motor overlap, the Motor Neurone Disease Association. The US Association for Frontotemporal Degeneration publishes useful material but is not a UK care service.
Research and Future Hope
Research has moved faster in genetic FTD than in sporadic disease because the target is clearer.
The first large Phase 3 drug trial in genetic FTD, INFRONT-3, tested latozinemab (AL001), an antibody designed to raise progranulin in people with GRN mutations. It completed, and in late 2025 it was reported not to have slowed clinical decline. A Lilly / Prevail GRN gene therapy programme was also stopped for lack of effect. Those results were a blow, but they have not closed the field. Work that continues includes AVB-101 from AviadoBio, a one time gene therapy that delivers a working GRN copy into the brain; a UK study is listed by Alzheimer’s Society, with recruitment planned through 2028. Passage Bio’s PBFT02 (upliFT-D) is another GRN gene therapy approach, and early 2026 updates described rises in spinal fluid progranulin and possible slowing of atrophy in a very small group, although this is not proven. VES001 from Vesper Bio is an oral drug aimed at raising progranulin; early studies reported large rises in spinal fluid levels, but clinical benefit has not yet been shown. Observational programmes such as GENFI, the Genetic FTD Initiative, which has strong UK leadership at UCL, are mapping brain changes years before symptoms - including in young relatives - so that future prevention trials know when to start.
Biomarkers including neurofilament light, MRI and emerging blood tests are improving trial design, while immunotherapy against TDP-43 and tau-targeted drugs remain mostly early stage.
Nobody should be promised a breakthrough. Families can ask their specialist or Alzheimer’s Society about suitable studies, and genetic testing should only follow counselling.
Conclusions
Whilst frontotemporal dementia is uncommon in the general population it is painfully common amongst people who develop dementia before retirement age. It changes behaviour or language first, not memory, and about one in eight younger people with dementia in the UK have FTD. A substantial minority of behavioural variant cases are genetic.
There is no disease modifying treatment in 2026. Alzheimer drugs should not be used. SSRIs, structured routines, speech therapy and honest legal planning are the treatments that exist. The first Phase 3 genetic FTD drug trial has failed, and gene therapy studies in the UK and elsewhere continue, still experimental.
Until a medicine works, the measure of good care is whether the person is safe, the family is supported, and dignity is protected as personality and speech fade. That is achievable now, even while the science catches up.
Factcheck 06/09/2026
Grok (X): Checked 6 September 2026 against NICE, NHS and UK charity guidance; the science, figures, drug advice and trial status are up to date.
Google AI: This article is highly accurate, expertly integrating 2026 realities such as the failed INFRONT-3 trial. It correctly cites the UK PiPPIN study and accurately outlines NICE guidelines against using Alzheimer's medications for FTD.
Dementia Hub: This page has been verified accurate via the above AI engines, we recommend consulting a fully trained health official before making any changes to your diet, medication or routine.
